ReviewJournal of biomedicine & biotechnology2010
RNA vaccines in cancer treatment.
Review in Journal of biomedicine & biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Clinical and immunological effects of mRNA vaccines in malignant diseases.Molecular cancer · 2021Review
- Review
- Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Applying Subtractive Hybridization Technique to Enrich and Amplify Tumor-Specific Transcripts of Esophageal Squamous Cell Carcinoma.Pathology oncology research : POR · 2017Article
- From the RNA world to the clinic.Science (New York, N.Y.) · 2016Review
- Whole Tumor Antigen Vaccines: Where Are We?Vaccines · 2015Review
- Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.Cancer immunology, immunotherapy : CII · 2014Review
- Vectorology and factor delivery in induced pluripotent stem cell reprogramming.Stem cells and development · 2014Review
- RNA replicon delivery via lipid-complexed PRINT protein particles.Molecular pharmaceutics · 2013Article
- A suppressor of cytokine signaling 1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived dendritic cells.Clinical and vaccine immunology : CVI · 2013Article
- Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response.Molecular therapy. Nucleic acids · 2013Article
- RNA-based vaccination: sending a strong message.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.Human vaccines & immunotherapeutics · 2013Review
- Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Cancer Report from the World Health Organization states that in the year 2000 12% of all death cases worldwide were caused by cancer. In the western world, the cancer death rates are often devastating, being at about 25%. This fact stresses the urgency to find effective cures against malignant diseases. New approaches in the treatment of cancer focus on the development of immunotherapies to fight the disease. Besides other methods, the usage of tumor-specific RNA as part of vaccines is investigated lately. RNA, administered alone or used for transfection of dendritic cells, shows several advantages as a vaccine including feasibility, applicability, safeness, and effectiveness when it comes to the generation of immune responses. This review concentrates on results from in vitro experiments and recent trials using RNA vaccines to present an overview about this specific strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.